Abstract
High-density lipoprotein (HDL) therapy is an emerging area of therapeutic development in the cardiovascular field, aimed at supplementing and improving the vascular benefit exerted by current treatments. Several studies have clearly established that HDL-cholesterol (HDL-C) levels are a potent and independent epidemiologic risk factor for cardiovascular diseases; moreover, studies in animal models have established that HDL-C raising interventions, such as overexpression of apolipoprotein A-I (apoA-I), the major HDL protein component, reduce the extent of atherosclerosis. In vitro and in vivo experiments have provided mechanistic explanations for the atheroprotective effects of HDL. HDL not only mediates reverse cholesterol transport, but also exerts antioxidant, anti-inflammatory, antithrombotic and vasodilatory effects. These multiple antiatherosclerotic properties provide an excellent rationale for designing therapeutic interventions targeted at enhancing HDL/apoA-I levels, but also for considering a direct administration of HDL-apoA-I in a variety of cardiovascular diseases. We provide an overview and an update of all therapeutic applications of synthetic HDL tested in animal models or in clinical trials. HDL therapy has proven to be effective in promoting atherosclerosis regression not only in experimental models, but also in humans, whereas applications to other areas of cardiovascular disease have only, up to now, been tested in animal models.
Keywords: High-density lipoprotein, apoA-I, apoA-IMilano, apoA-I mimetic peptides, atherosclerosis, restenosis, ischemia/reperfusion injury
Current Vascular Pharmacology
Title: HDL Therapy for the Treatment of Cardiovascular Diseases
Volume: 7 Issue: 4
Author(s): Cinzia Parolini, Marta Marchesi and Giulia Chiesa
Affiliation:
Keywords: High-density lipoprotein, apoA-I, apoA-IMilano, apoA-I mimetic peptides, atherosclerosis, restenosis, ischemia/reperfusion injury
Abstract: High-density lipoprotein (HDL) therapy is an emerging area of therapeutic development in the cardiovascular field, aimed at supplementing and improving the vascular benefit exerted by current treatments. Several studies have clearly established that HDL-cholesterol (HDL-C) levels are a potent and independent epidemiologic risk factor for cardiovascular diseases; moreover, studies in animal models have established that HDL-C raising interventions, such as overexpression of apolipoprotein A-I (apoA-I), the major HDL protein component, reduce the extent of atherosclerosis. In vitro and in vivo experiments have provided mechanistic explanations for the atheroprotective effects of HDL. HDL not only mediates reverse cholesterol transport, but also exerts antioxidant, anti-inflammatory, antithrombotic and vasodilatory effects. These multiple antiatherosclerotic properties provide an excellent rationale for designing therapeutic interventions targeted at enhancing HDL/apoA-I levels, but also for considering a direct administration of HDL-apoA-I in a variety of cardiovascular diseases. We provide an overview and an update of all therapeutic applications of synthetic HDL tested in animal models or in clinical trials. HDL therapy has proven to be effective in promoting atherosclerosis regression not only in experimental models, but also in humans, whereas applications to other areas of cardiovascular disease have only, up to now, been tested in animal models.
Export Options
About this article
Cite this article as:
Parolini Cinzia, Marchesi Marta and Chiesa Giulia, HDL Therapy for the Treatment of Cardiovascular Diseases, Current Vascular Pharmacology 2009; 7 (4) . https://dx.doi.org/10.2174/157016109789043856
DOI https://dx.doi.org/10.2174/157016109789043856 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Polyphenols: A Nutraceutical Approach Against Diseases
Recent Patents on Food, Nutrition & Agriculture Mutation p.S335X in GATA4 Reduces its DNA Binding Affinity and Enhances Cell Apoptosis Associated with Ventricular Septal Defect
Current Molecular Medicine Cardiovascular Complications of Obesity
Current Respiratory Medicine Reviews Thrombophilia in Pregnancy: Maternal and Fetal Implications
Current Women`s Health Reviews A Review of Recent Patents (2016-2019) on Plant Food Supplements with Potential Application in the Treatment of Neurodegenerative and Metabolic Disorders
Recent Patents on Food, Nutrition & Agriculture Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature
Current Cardiology Reviews Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Targeting Water in the Brain: Role of Aquaporin-4 in Ischemic Brain Edema
Current Drug Targets Modulation of Stem Cell Differentiation by the Influence of Nanobiomaterials/ Carriers
Current Stem Cell Research & Therapy Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism The Effect of Chronic Co-Administration of Morphine and Verapamil on Isoproterenol-Induced Heart Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Soy Isoflavones and Cardiovascular Health: An Update
Current Nutrition & Food Science The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Osteoporosis Entwined with Cardiovascular Disease: The Implication of Osteoprotegerin and the Example of Statins
Current Medicinal Chemistry Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel
Current Vascular Pharmacology